Zydus Life Science Gets CDSCO Panel Nod To Manufacture and Market Anti-cancer Drug Nelarabine
New Delhi: In a significant development, the drug major Zydus Life Science has got approval from the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organization (CDSCO) to manufacture and market the anti-cancer drug Nelarabine Injection 250 mg/50 mL (5 mg/mL).
However, this approval is subject to the condition that the drug should be sold by retail under the prescription of an oncologist only, and the firm should conduct a Phase IV clinical trial.
This came after the firm presented their proposal for the manufacture & marketing of Nelarabine Injection 250 mg/50 mL (5 mg/mL), along with a request for a BE waiver and a local Phase III clinical trial waiver.
Nelarabine is a purine nucleoside analog and antineoplastic agent used for the treatment of acute T-cell lymphoblastic leukemia and T-cell lymphoblastic lymphoma with inadequate clinical response to prior chemotherapeutic treatments.
The drug is indicated for the treatment of patients with T-cell acute lymphoblastic leukaemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL) whose disease has not responded to or has relapsed following treatment with at least two chemotherapy regimens.
The committee noted that the drug is approved in the USA and EU as an orphan drug.
Also Read:Zuventus Healthcare gets CDSCO Panel Nod To Manufacture, Market Edoxaban film-coated tablets
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.